Disease Control and Prevention Vaccine Market Top Leading Players with Strategies and Forecast 2027

The global disease control and prevention vaccine market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Disease Control means reducing the number of new infections and the number of people infected by them or the number of people getting sick or dying from a disease in local settings. Additionally, vaccines are biological entities that are used to activate acquired immunity to offer control or prevent a particular disease or a group of diseases. The major factor driving the demand for disease control and prevention vaccine is the technological advancements and new product launches in the vaccines to control, prevent, and eradicate diseases across the globe.

For instance, in October 2021, Pfizer announced that it has received the Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine from the US Food and Drug Administration (FDA). This is intended for children 5 through 11 years of age. Additionally, in June 2021, Merck announced the launch of VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) in the US. It was developed in partnership with Sanofi Pasteur.

To Request a Sample of our Report on Disease Control and Prevention Vaccine Market: https://www.omrglobal.com/request-sample/disease-control-and-prevention-vaccine-market

Some major players in the market include Merck & Co., Inc., GlaxoSmithKline plc, Sanofi SA, and Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2021, GSK announced that it has received approval for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) from the US FDA. It is used for the prevention of shingles (herpes zoster) in adults 18 years of age and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression.

Market Coverage

· The market number available for - 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

Segment Covered-

· By Type

· By Indication

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Merck & Co., Inc., GlaxoSmithKline plc, Sanofi SA, and Pfizer Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Disease Control and Prevention Vaccine Market is Available @ https://www.omrglobal.com/industry-reports/disease-control-and-prevention-vaccine-market

Global Disease Control and Prevention Vaccine Market Report by Segment

By Type

• Live-Attenuated Vaccines

• Inactivated Vaccines

• Recombinant Vaccines

• Toxoid Vaccines

By Indication

• Infectious Disease

• Cancer

• Other Indication

Global Disease Control and Prevention Vaccine Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.